Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IDYA NASDAQ:OCUL NASDAQ:TARS NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$24.61-1.3%$23.94$13.45▼$37.80$2.18B0.121.19 million shs1.05 million shsOCULOcular Therapeutix$12.81+0.3%$12.03$5.78▼$13.85$2.22B1.52.13 million shs1.84 million shsTARSTarsus Pharmaceuticals$49.36-4.8%$48.63$30.23▼$59.76$2.19B0.81629,329 shs1.23 million shsXNCRXencor$8.60+1.2%$8.32$6.92▼$27.24$606.25M0.82694,801 shs791,753 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences-1.28%-9.39%+0.78%+10.96%-32.02%OCULOcular Therapeutix+0.31%-5.81%+2.48%+46.74%+51.78%TARSTarsus Pharmaceuticals-4.84%-14.35%-6.37%+20.71%+55.22%XNCRXencor+1.18%+0.58%+11.40%-6.42%-59.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$24.61-1.3%$23.94$13.45▼$37.80$2.18B0.121.19 million shs1.05 million shsOCULOcular Therapeutix$12.81+0.3%$12.03$5.78▼$13.85$2.22B1.52.13 million shs1.84 million shsTARSTarsus Pharmaceuticals$49.36-4.8%$48.63$30.23▼$59.76$2.19B0.81629,329 shs1.23 million shsXNCRXencor$8.60+1.2%$8.32$6.92▼$27.24$606.25M0.82694,801 shs791,753 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences-1.28%-9.39%+0.78%+10.96%-32.02%OCULOcular Therapeutix+0.31%-5.81%+2.48%+46.74%+51.78%TARSTarsus Pharmaceuticals-4.84%-14.35%-6.37%+20.71%+55.22%XNCRXencor+1.18%+0.58%+11.40%-6.42%-59.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIDYAIDEAYA Biosciences 2.81Moderate Buy$42.8574.10% UpsideOCULOcular Therapeutix 3.00Buy$17.2034.27% UpsideTARSTarsus Pharmaceuticals 2.71Moderate Buy$66.6735.06% UpsideXNCRXencor 2.67Moderate Buy$22.25158.72% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, TARS, IDYA, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.009/9/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.009/9/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IDYAIDEAYA BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$36.009/5/2025TARSTarsus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIDYAIDEAYA Biosciences$7M308.12N/AN/A$12.25 per share2.01OCULOcular Therapeutix$63.72M34.98N/AN/A$2.01 per share6.37TARSTarsus Pharmaceuticals$182.95M11.39N/AN/A$5.87 per share8.41XNCRXencor$146.93M4.17N/AN/A$9.63 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest XNCR, TARS, IDYA, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIDYAIDEAYA BiosciencesN/A12.3912.39OCULOcular Therapeutix0.2310.1010.02TARSTarsus Pharmaceuticals0.225.265.21XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIDYAIDEAYA Biosciences98.29%OCULOcular Therapeutix59.21%TARSTarsus Pharmaceuticals90.01%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipIDYAIDEAYA Biosciences2.50%OCULOcular Therapeutix2.30%TARSTarsus Pharmaceuticals8.97%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableXNCRXencor28071.32 million67.93 millionOptionableXNCR, TARS, IDYA, and OCUL HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Buys 384,509 Shares of Xencor, Inc. $XNCRSeptember 10 at 5:04 AM | marketbeat.com155,580 Shares in Xencor, Inc. $XNCR Bought by Cubist Systematic Strategies LLCSeptember 9, 2025 | marketbeat.comTrexquant Investment LP Acquires 50,119 Shares of Xencor, Inc. $XNCRSeptember 8, 2025 | marketbeat.comRBC Cuts Xencor (XNCR) Price Target but Keeps Outperform RatingSeptember 8, 2025 | msn.comXencor (NASDAQ:XNCR) Cut to Neutral at Bank of AmericaSeptember 6, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Gap Down Following Analyst DowngradeSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Cut to "Neutral" at Bank of AmericaSeptember 5, 2025 | marketbeat.comBVF Inc. IL Buys 451,381 Shares of Xencor, Inc. $XNCRSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Gap Down After Analyst DowngradeSeptember 5, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Trading Up 6% - What's Next?September 4, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Holdings in Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comB of A Securities Downgrades Xencor (XNCR)September 4, 2025 | msn.comPanagora Asset Management Inc. Acquires 260,124 Shares of Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | americanbankingnews.comXencor downgraded to Neutral from Buy at BofASeptember 3, 2025 | msn.comBeyond The Numbers: 4 Analysts Discuss Xencor StockSeptember 3, 2025 | benzinga.comXencor downgraded to Neutral at BofA on long development timelinesSeptember 3, 2025 | msn.comBraidwell LP Boosts Stock Position in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNantahala Capital Management LLC Purchases New Shares in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Purchases 34,765 Shares of Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXNCR, TARS, IDYA, and OCUL Company DescriptionsIDEAYA Biosciences NASDAQ:IDYA$24.61 -0.32 (-1.28%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.60 0.00 (-0.02%) As of 09/12/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$12.81 +0.04 (+0.31%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.80 -0.01 (-0.04%) As of 09/12/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$49.36 -2.51 (-4.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$49.34 -0.02 (-0.03%) As of 09/12/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Xencor NASDAQ:XNCR$8.60 +0.10 (+1.18%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.56 -0.04 (-0.52%) As of 09/12/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
